NCT05396495 is a NA clinical trial of NeurolyserXR in Sacroiliitis, sponsored by FUSMobile Inc..

Who is sponsoring NCT05396495?

NCT05396495 is sponsored by FUSMobile Inc..

What drugs are being tested in NCT05396495?

Interventions in NCT05396495: NeurolyserXR.

What condition does NCT05396495 study?

NCT05396495 studies Sacroiliitis.

Is NCT05396495 still recruiting?

NCT05396495 is currently status unknown. Last updated 7 September 2023.

Last reviewed 2023-09-07 · How we verify

NCT05396495

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Feasibility of the NeurolyserXR for Sacroiliac Joint Pain

Status unknown NA Last updated 7 September 2023

What this trial tests

NA trial testing NeurolyserXR in Sacroiliitis in 10 participants. Status unknown.

Timeline

24 October 2022

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	FUSMobile Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	24 October 2022
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across Israel

Drugs / interventions tested

NeurolyserXR

Conditions studied

Sacroiliitis — all drugs for Sacroiliitis →

Sponsor

FUSMobile Inc.

Who can join

Adults 18 to 80, any sex, with Sacroiliitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study to evaluate the safety and the effectiveness of the Neurolyser XR as a treatment for sacroiliitis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sacroiliitis

Currently open trials in the same condition.

NCT06053255 — Use of the Neurolyser XR for the Treatment of Low Back Pain Related to Sacroiliitis · NA · recruiting
NCT05715463 — Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity · NA · active not recruiting
NCT05276024 — Evaluation of the IFuse Bedrock Technique in Association with Posterior Lumbosacral Fusion with Iliac Fixation. · recruiting

Other FUSMobile Inc. trials

Trials by the same sponsor.

NCT06053255 — Use of the Neurolyser XR for the Treatment of Low Back Pain Related to Sacroiliitis · NA · recruiting
NCT05154448 — Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain · NA · completed
NCT04519541 — RAMBAM 021: Safety and Initial Feasibility of the Neurolyser XR for the Treatment of Chronic Low Back Pain · NA · completed
NCT05122611 — Post Lumbar Radiofrequency Neurotomy Imaging · completed
NCT04129034 — Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05396495 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FUSMobile Inc.
Last refreshed: 7 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05396495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing